Skip to main content

Table 3 Multivariate proportional hazards models by treatment arm

From: Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

STAD + RT Arm(n = 45)

Endpoints

Covariate

Comparison

HR*

95% CI

p-value**

 

Overall Survival

VEGF

0-1 vs.

RL

(0.734, 2.745)

0.299

2-3

1.419

Age

< 71 vs.

RL

(0.608, 2.910)

0.475

≥ 71

1.330

Combined Gleason Score

2-6 vs.

RL

(0.393, 2.581)

0.988

7-10

1.007

Clinical Stage

T2 vs.

RL

(0.213, 1.196)

0.120

T3

0.505

Distant Metastasis

VEGF

0-1 vs.

RL

(0.264, 1.326)

0.200

2-3

0.592

Age

< 71 vs.

RL

(0.813, 6.614)

0.120

≥71

2.318

Combined Gleason Score

2-6 vs.

RL

(1.622,61.105)

0.013

7-10

9.957

Clinical Stage

T2 vs.

RL

(0.376, 3.580)

0.800

T3

1.160

Local Progression

VEGF

0-1vs.

RL

(0.321, 2.064)

0.660

2-3

0.814

Age

< 71 vs.

RL

( 0.288, 3.515)

0.990

≥71

1.006

Combined Gleason Score

2-6 vs.

RL

(0.420, 9.427)

0.390

7-10

1.990

Clinical Stage

T2 vs.

RL

(0.146, 1.755)

0.280

T3

0.506

Disease-free Survival

VEGF

0-1vs.

RL

(0.273, 0.995)

0.048

2-3

0.521

Age

< 71 vs.

RL

(0.807, 3.601)

0.162

≥ 71

1.705

Combined Gleason Score

2-6 vs.

RL

(0.792, 4.567)

0.150

7-10

1.902

Clinical Stage

T2 vs.

RL

(0.403, 2.054)

0.052

T3

0.910

Biochemical Failure

VEGF

0-1vs.

RL

(0.251, 1.170)

0.120

2-3

0.542

Age

< 71 vs.

RL

(0.805, 3.834)

0.160

≥ 71

1.757

Combined Gleason Score

2-6 vs.

RL

(0.783, 14.343)

0.100

7-10

3.352

Clinical Stage

T2 vs.

RL

(0.425, 3.151)

0.780

T3

1.157

RT Alone Arm(n = 58)

Endpoints

Covariate

Comparison

HR*

95% CI

p-value**

Overall Survival

VEGF

0-1 vs.

RL

(0.622, 2.028)

0.699

2-3

1.123

Age

< 71 vs.

RL

(0.890, 2.800)

0.118

≥ 71

1.579

Combined Gleason Score

2-6 vs.

RL

(0.839, 2.566)

0.178

7-10

1.468

Clinical Stage

T2 vs.

RL

(0.760, 2.917)

0.246

T3

1.489

Distant Metastasis

VEGF

0-1 vs.

RL

(0.777, 3.319)

0.200

2-3

1.606

Age

< 71 vs.

RL

(0.422, 1.706)

0.640

≥71

0.848

Combined Gleason Score

2-6 vs.

RL

(0.992, 3.825)

0.053

7-10

1.947

Clinical Stage

T2 vs.

RL

(0.357, 1.789)

0.590

T3

0.800

Local Progression

VEGF

0-1vs.

RL

(0.670, 2.669)

0.410

2-3

1.337

Age

< 71 vs.

RL

(0.391, 1.643)

0.540

≥71

0.801

Combined Gleason Score

2-6 vs.

RL

(0.259, 1.067)

0.075

7-10

0.525

Clinical Stage

T2 vs.

RL

(0.415, 1.971)

0.800

T3

0.905

Disease-free Survival

VEGF

0-1vs.

RL

(0.779, 2.371)

0.279

2-3

1.359

Age

< 71 vs.

RL

(0.305, 0.979)

0.042

≥ 71

0.547

Combined Gleason Score

2-6 vs.

RL

(1.021, 3.537)

0.043

7-10

1.900

Clinical Stage

T2 vs.

RL

(0.473, 1.913)

0.889

T3

0.952

Biochemical Failure

VEGF

0-1vs.

RL

(0.815, 2.562)

0.210

2-3

1.446

Age

< 71 vs.

RL

(0.315, 1.104)

0.056

≥ 71

0.565

Combined Gleason Score

2-6 vs.

RL

(0.655, 2.356)

0.510

7-10

1.242

Clinical Stage

T2 vs.

RL

(0.474, 2.459)

0.850

   

T3

1.080

  
  1. * A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A hazard ratio of 1 indicates no difference between two subgroups.
  2. ** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure) Proportional Hazards Model.
  3. indicates the statistically significant at the significance level of 0.05.
  4. 1 patient without Gleason score is not included.